Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma von Ramakrishnan, Vijay G, Miller, Kevin C, Macon, Elaine P, Kimlinger, Teresa K, Haug, Jessica, Kumar, Sanjay, Gonsalves, Wilson I, Rajkumar, S Vincent, Kumar, Shaji K

Volltext

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial von GALANIS, Evanthia, KEITH ANDERSON, S, KAUFMANN, Timothy J, BUCKNER, Jan C, LAFKY, Jackie M, UHM, Joon H, GIANNINI, Caterina, KUMAR, Shaji K, KIMLINGER, Teresa K, NORTHFELT, Donald W, FLYNN, Patrick J, JAECKLE, Kurt A

Volltext

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma von Alsayed, Yazan, Ngo, Hai, Runnels, Judith, Leleu, Xavier, Singha, Ujjal K., Pitsillides, Costas M., Spencer, Joel A., Kimlinger, Teresa, Ghobrial, Joanna M., Jia, Xiaoying, Lu, Ganwei, Timm, Michael, Kumar, Ashok, Côté, Daniel, Veilleux, Israel, Hedin, Karen E., Roodman, G. David, Witzig, Thomas E., Kung, Andrew L., Hideshima, Teru, Anderson, Kenneth C., Lin, Charles P., Ghobrial, Irene M.

Volltext

Immunophenotyping in multiple myeloma and related plasma cell disorders von Kumar, Shaji, MD, Kimlinger, Teresa, BA, Morice, William, MD, PhD

Volltext

Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway von Ramakrishnan, Vijay, Kimlinger, Teresa, Haug, Jessica, Painuly, Utkarsh, Wellik, Linda, Halling, Timothy, Rajkumar, S Vincent, Kumar, Shaji

Volltext

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression von Kumar, Shaji, Witzig, Thomas E., Timm, Michael, Haug, Jessica, Wellik, Linda, Kimlinger, Teresa K., Greipp, Philip R., Rajkumar, S. Vincent

Volltext

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells von Ramakrishnan, Vijay, Kimlinger, Teresa, Haug, Jessica, Timm, Michael, Wellik, Linda, Halling, Timothy, Pardanani, Animesh, Tefferi, Ayalew, Vincent Rajkumar, Sundararasan, Kumar, Shaji

Volltext

Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin von Ramakrishnan, Vijay, Timm, Michael, Haug, Jessica L., Kimlinger, Teresa K., Halling, Timothy, Wellik, Linda E., Witzig, Thomas E., Vincent Rajkumar, S., Adjei, Alex A., Kumar, Shaji

Volltext

R-(-)−gossypol (AT-101) activates programmed cell death in multiple myeloma cells von Kline, Michael P, Rajkumar, S. Vincent, Timm, Michael M, Kimlinger, Teresa K, Haug, Jessica L, Lust, John A, Greipp, Philip R, Kumar, Shaji

Volltext

Detection of Circulating Cytokeratin-positive Cells in the Blood of Breast Cancer Patients Using Immunomagnetic Enrichment and Digital Microscopy von WITZIG, Thomas E, BOSSY, Blaise, BAUER, Kenneth D, KIMLINGER, Teresa, ROCHE, Patrick C, INGLE, James N, GRANT, Clive, DONOHUE, John, SUMAN, Vera J, HARRINGTON, Douglas, TORRE-BUENO, Jose

Volltext

Fish is superior to PCR in detecting t(14;18)(q32;q21)-IgH/bcl-2 in follicular lymphoma using paraffin-embedded tissue samples von EINERSON, Richard R, KURTIN, Paul J, DAYHARSH, Gerald A, KIMLINGER, Teresa K, REMSTEIN, Ellen D

Volltext

Expression of CD52 on plasma cells in plasma cell proliferative disorders von Kumar, Shaji, Kimlinger, Teresa K., Lust, John A., Donovan, Kathleen, Witzig, Thomas E.

Volltext

Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma von Ramakrishnan, V, Painuly, U, Kimlinger, T, Haug, J, Rajkumar, S V, Kumar, S

Volltext

Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma von Kloeber, Jake A., Kimlinger, Teresa K., Haug, Jessica L., Henderson, Kimberly J., Rajkumar, S.Vincent, Kumar, Shaji K.

Volltext

Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers von Bansal, Radhika, Kimlinger, Teresa, Gyotoku, Kelli Ann, Smith, Matthew, Rajkumar, Vincent, Kumar, Shaji

Volltext

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma von Binder, Moritz, Rajkumar, S. Vincent, Lacy, Martha Q., Haug, Jessica L., Dispenzieri, Angela, Henderson, Kimberly J., Kimlinger, Teresa K., Kumar, Shaji K.

Volltext

Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma von Binder, Moritz, Rajkumar, S. Vincent, Lacy, Martha Q., Haug, Jessica L., Dispenzieri, Angela, Henderson, Kimberly J., Kimlinger, Teresa K., Stewart, A. Keith, Bergsagel, P. Leif, Kumar, Shaji K.

Volltext

Abstract 3909: HDAC inhibition in combination with MEK or BCL-2 inhibition as novel therapeutic strategies in multiple myeloma von Miller, Kevin C., Haug, Jessica, Kimlinger, Teresa, Kumar, Sanjay, Gonsalves, Wilson, Rajkumar, S. Vincent, Kumar, Shaji K., Ramakrishnan, Vijay

Volltext

Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease von Pardanani, Animesh, Reeder, Terra L., Kimlinger, Teresa K., Baek, Jin Y., Li, Chin-Y., Butterfield, Joseph H., Tefferi, Ayalew

Volltext

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma von Ramakrishnan, V, Ansell, S, Haug, J, Grote, D, Kimlinger, T, Stenson, M, Timm, M, Wellik, L, Halling, T, Rajkumar, S V, Kumar, S

Volltext